Background: Efficient theranostic strategies concurrently bring and use both the therapeutic and diagnostic features, serving as a cutting-edge tool to combat advanced cancers. Goals of the Investigation: Here, we develop stimuli-sensitive theranostics consisting of tailored copolymers forming micellar conjugates carrying pyropheophorbide-a (PyF) attached by pH-sensitive hydrazone bonds, thus enabling the tumor microenvironment-sensitive activation of the photodynamic therapy (PDT) effect, fluorescence or phosphorescence. Results: The nanomedicines show superior anti-tumor PDT efficacy and huge tumor-imaging potential, while reducing their accumulation, and potentially side effects, in the liver and spleen. The developed theranostics exhibit clear selective tumor accumulation at high levels in the mouse sarcoma S180 tumor model with almost no PyF found in the healthy tissues after 48 h. Once in the tumor, illumination at λexc = 420 nm reaches the therapeutic effect due to the 1O2 generation. Indeed, an almost complete inhibition of tumor growth is observed up to 18 days after the treatment. Conclusion: The clear benefit of the specific PyF release and activation in the acidic tumor environment for the targeted delivery and tissue distribution dynamics was proved. Conjugates carrying pyropheophorbide-a (PyF) attached by pH-sensitive hydrazone bonds showed their excellent antitumor PDT effect and its applicability as advanced theranostics at very low dose of PyF.

Institute of Macromolecular Chemistry Czech Academy of Sciences Heyrovského nám 2 16200 Prague Czech Republic

Institute of Physics Photobiophysics Humboldt University of Berlin Newtonstr 15 12489 Berlin Germany

Laboratory of Microbiology and Oncology Faculty of Pharmaceutical Sciences Sojo University Kumamoto 860 0082 Japan

Zobrazit více v PubMed

Hu TT, Wang ZD, Shen WC, Liang RZ, Yan D, Wei M. Recent advances in innovative strategies for enhanced cancer photodynamic therapy. Theranostics. 2021;11:3278–300. PubMed PMC

Abrahamse H, Hamblin MR. New photosensitizers for photodynamic therapy. Biochem J. 2016;473:347–64. PubMed PMC

van Straten D, Mashayekhi V, de Bruijn HS, Oliveira S, Robinson DJ. Oncologic photodynamic therapy: Basic principles, current clinical status and future directions. Cancers. 2017;9:19. PubMed PMC

Kwiatkowski S, Knap B, Przystupski D, Saczko J, Kedzierska E, Knap-Czop K. et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098–107. PubMed

Kumar A, Morales O, Mordon S, Delhem N, Boleslawski E. Could photodynamic therapy be a promising therapeutic modality in hepatocellular carcinoma patients? A critical review of experimental and clinical studies. Cancers. 2021;13:5176. PubMed PMC

Fang J, Šubr V, Islam W, Hackbarth S, Islam R, Etrych T. et al. N-(2-Hydroxypropyl)methacrylamide polymer conjugated pyropheophorbide-a, a promising tumor-targeted theranostic probe for photodynamic therapy and imaging. Eur J Pharm Biopharm. 2018;130:165–76. PubMed

Fang J, Liao L, Yin H, Nakamura H, Šubr V, Ulbrich K, Photodynamic therapy and imaging based on tumor-targeted nanoprobe, polymer-conjugated zinc protoporphyrin. Future Sci OA. 2015: 1: FSO4. PubMed PMC

dos Santos AF, de Almeida DRQ, Terra LF, Baptista MS, Labriola L. Photodynamic therapy in cancer treatment - an update review. J Cancer Metastatis Treat. 2019;5:25.

Shi XT, Zhang CY, Gao J, Wang ZJ. Recent advances in photodynamic therapy for cancer and infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11:e1560. PubMed PMC

Hadjipanayis CG, Stummer W. 5-ALA and FDA approval for glioma surgery. J Neurooncol. 2019;141:479–86. PubMed PMC

Hadjipanayis CG, Stummer W, Sheehan JP. 5-ALA fluorescence-guided surgery of CNS tumors. J Neurooncol. 2019;141:477–8. PubMed

Vermandel M, Dupont C, Lecomte F, Leroy HA, Tuleasca C, Mordon S. et al. Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial. J Neurooncol. 2021;152:501–14. PubMed

Schipmann S, Muther M, Stogbauer L, Zimmer S, Brokinkel B, Holling M. et al. Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control. J Neurosurg. 2021;134:426–36. PubMed

Dolmans DEJG, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3:380–7. PubMed

Cuenca RE, Allison RR, Sibata C, Downie GH. Breast cancer with chest wall progression: Treatment with photodynamic therapy. Ann Surg Oncol. 2004;11:322–7. PubMed

Muschter R. Photodynamic therapy: A new approach to prostate cancer. Curr Urol Rep. 2003;4:221–8. PubMed

Loning M, Diddens H, Kupker W, Diedrich K, Huttmann G. Laparoscopic fluorescence detection of ovarian carcinoma Metastases using 5-aminolevulinic acid-induced protoporphyrin IX. Cancer. 2004;100:1650–6. PubMed

Goff BA, Blake J, Bamberg MP, Hasan T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br J Cancer. 1996;74:1194–8. PubMed PMC

Senior K. Photodynamic therapy for bladder cancer. Lancet Oncol. 2005;6:546. PubMed

Bhuvaneswari R, Yuen GY, Chee SK, Olivo M. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. Photochem Photobiol Sci. 2007;6:1275–83. PubMed

Roberts DJH, Cairnduff F. Photodynamic therapy of primary skin-cancer - a review. Br J Plast Surg. 1995;48:360–70. PubMed

Biel MA. Photodynamic therapy of head and neck cancers. In: Gomer CJ, editor. Photodynamic Therapy: Methods and Protocols: Humana Totowa, NJ. 2010. p. 281-93.

Wen X, Li Y, Hamblin MR. Photodynamic therapy in dermatology beyond non-melanoma cancer: An update. Photodiagnosis Photodyn Ther. 2017;19:140–52. PubMed PMC

Triesscheijn M, Baas P, Schellens JHM, Stewart FA. Photodynamic therapy in oncology. Oncologist. 2006;11:1034–44. PubMed

Moole H, Tathireddy H, Dharmapuri S, Moole V, Boddireddy R, Yedama P. et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis. World J Gastroenterol. 2017;23:1278–88. PubMed PMC

Yano T, Hatogai K, Morimoto H, Yoda Y, Kaneko K. Photodynamic therapy for esophageal cancer. Ann Transl Med. 2014;2:29. PubMed PMC

Li L, Huh KM. Polymeric nanocarrier systems for photodynamic therapy. Biomater Res. 2014;18:19. PubMed PMC

Nonaka T, Nanashima A, Nonaka M, Uehara M, Isomoto H, Nonaka Y. et al. Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinoma. J Hepatobiliary Pancreat Sci. 2011;18:592–600. PubMed

Kato H, Furukawa K, Sato M, Okunaka T, Kusunoki Y, Kawahara M. et al. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer. 2003;42:103–11. PubMed

Yakavets I, Millard M, Zorin V, Lassalle HP, Bezdetnaya L. Current state of the nanoscale delivery systems for temoporfin-based photodynamic therapy: Advanced delivery strategies. J Control Release. 2019;304:268–87. PubMed

Zhang J, Jiang CS, Longo JPF, Azevedo RB, Zhang H, Muehlmann LA. An updated overview on the development of new photosensitizers for anticancer photodynamic therapy. Acta Pharm Sin B. 2018;8:137–46. PubMed PMC

Brasseur N, Ali H, Langlois R, Vanlier JE. Biological-activities of phthalocyanines.9. Photosensitization of V-79 chinese-hamster cells and Emt-6 mouse mammary-tumor by selectively sulfonated zinc phthalocyanines. Photochem Photobiol. 1988;47:705–11. PubMed

Rosenthal I. Phthalocyanines as photodynamic sensitizers. Photochem Photobiol. 1991;53:859–70. PubMed

Ris HB, Altermatt HJ, Inderbitzi R, Hess R, Nachbur B, Stewart JCM. et al. Photodynamic therapy with chlorins for diffuse malignant mesothelioma - initial clinical-results. Br J Cancer. 1991;64:1116–20. PubMed PMC

Borgia F, Giuffrida R, Caradonna E, Vaccaro M, Guarneri F, Cannavo SP. Early and late onset side effects of photodynamic therapy. Biomedicines. 2018;6:12. PubMed PMC

Dougherty TJ. Photosensitizers - therapy and detection of malignant-tumors. Photochem Photobiol. 1987;45:879–89. PubMed

Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986;46:6387–92. PubMed

Maeda H. The 35th Anniversary of the discovery of EPR Effect: A new wave of nanomedicines for tumor-targeted drug delivery—personal remarks and future prospects J Pers Med. 2021; 11: 229. PubMed PMC

Maeda H. The EPR effect: Its history, development and future implication. Drug Deliv Syst. 2018;33:80–8.

Kadkhoda J, Tarighatnia A, Barar J, Aghanejad A, Davaran S. Recent advances and trends in nanoparticles based photothermal and photodynamic therapy. Photodiagnosis Photodyn Ther. 2022;37:102697. PubMed

Lee D, Kwon S, Jang SY, Park E, Lee Y, Koo H. Overcoming the obstacles of current photodynamic therapy in tumors using nanoparticles. Bioact Mater. 2022;8:20–34. PubMed PMC

Ji B, Wei M, Yang B. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy. Theranostics. 2022;12:434–58. PubMed PMC

Chepurna OM, Yakovliev A, Ziniuk R, Nikolaeva OA, Levchenko SM, Xu H. et al. Core-shell polymeric nanoparticles co-loaded with photosensitizer and organic dye for photodynamic therapy guided by fluorescence imaging in near and short-wave infrared spectral regions. J Nanobiotechnology. 2020;18:19. PubMed PMC

Pappalardo A, Gangemi CMA, Testa C, Sfrazzetto GT. Supramolecular assemblies for photodynamic therapy. Curr Org Chem. 2021;25:963–93.

Skupin-Mrugalska P, Piskorz J, Goslinski T, Mielcarek J, Konopka K, Duzgunes N. Current status of liposomal porphyrinoid photosensitizers. Drug Discov Today. 2013;18:776–84. PubMed

Wang G, Su Y, Chen X, Zhou Y, Huang P, Huang W. et al. H2O2-responsive polymer prodrug nanoparticles with glutathione scavenger for enhanced chemo-photodynamic synergistic cancer therapy. Bioact Mater. 2023;25:189–200. PubMed PMC

Wang G, Huang P, Wang L, Chen X, Zhou Y, Huang W. et al. ROS-responsive thioether-containing hyperbranched polymer micelles for light-triggered drug release. SmartMat. 2022;3:522–31.

Nakamura H, Liao L, Hitaka Y, Tsukigawa K, Šubr V, Fang J. et al. Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo. J Control Release. 2013;165:191–8. PubMed

Korolchuk AM, Zolottsev VA, Misharin AY. Conjugates of tetrapyrrolic macrocycles as potential anticancer target-oriented photosensitizers. Top Curr Chem. 2023;381:10. PubMed

Ulbrich K, Šubr V. Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliv Rev. 2010;62:150–66. PubMed

Ulbrich K, Holá K, Šubr V, Bakandritsos A, Tuček J, Zbořil R. Targeted drug delivery with polymers and magnetic nanoparticles: Covalent and noncovalent approaches, release control, and clinical studies. Chem Rev. 2016;116:5338–431. PubMed

Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R. et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009;34:1629–36. PubMed

Duncan R, Vicent MJ. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev. 2010;62:272–82. PubMed

Islam W, Fang J, Imamura T, Etrych T, Šubr V, Ulbrich K. et al. Augmentation of the enhanced permeability and retention effect with nitric oxide-generating agents improves the therapeutic effects of nanomedicines. Mol Cancer Ther. 2018;17:2643–53. PubMed

Fang J, Islam R, Islam W, Yin H, Šubr V, Etrych T. et al. Augmentation of EPR effect and therapeutic efficacy of nanomedicine by carbon monoxide generating agents. Pharmaceutics. 2019;11:343. PubMed PMC

Islam R, Gao S, Islam W, Šubr V, Zhou J, Yokomizo K. et al. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines. Acta Biomater. 2021;126:372–83. PubMed

Zhao L, Kim TH, Kim HW, Kim SY. Pheophorbide a-conjugated pH-sensitive nanoparticle vectors for highly efficient photodynamic therapy of cancer. Int J Polym Mater Polym Biomater. 2015;64:733–44.

Xue XD, Huang Y, Bo RN, Jia B, Wu H, Yuan Y. et al. Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nat Commun. 2018;9:3653. PubMed PMC

Choi J, Kim SY. Photothermally enhanced photodynamic therapy based on glutathione-responsive pheophorbide a-conjugated gold nanorod formulations for cancer theranostic applications. J Ind Eng Chem. 2020;85:66–74.

Kim WL, Cho H, Li L, Kang HC, Huh KM. Biarmed poly(ethylene glycol)-(pheophorbide a)2 conjugate as a bioactivatable delivery carrier for photodynamic therapy. Biomacromolecules. 2014;15:2224–34. PubMed

Chytil P, Etrych T, Kříž J, Šubr V, Ulbrich K. N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour-targeting. Synthesis by RAFT polymerisation and physicochemical characterisation. Eur J Pharm Sci. 2010;41:473–82. PubMed

Ulbrich K, Etrych T, Chytil P, Jelínková M, Říhová B. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J Drug Target. 2004;12:477–89. PubMed

Ishitake K, Satoh K, Kamigaito M, Okamoto Y. Stereogradient polymers formed by controlled/living radical polymerization of bulky methacrylate monomers. Angew Chem Int Ed Engl. 2009;48:1991–4. PubMed

Perrier S, Takolpuckdee P, Mars CA. Reversible addition-fragmentation chain transfer polymerization: End group modification for functionalized polymers and chain transfer agent recovery. Macromolecules. 2005;38:2033–6.

Koziolová E, Kostka L, Kotrchová L, Šubr V, Konefal R, Nottelet B. et al. HPMA-based linear, diblock and star-like polymer drug carriers: advanced process for their simple production. Biomacromolecules. 2018;19:4003–13. PubMed

Etrych T, Mrkvan T, Chytil P, Koňák C, Říhová B, Ulbrich K. N-(2-hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation. J Appl Polym Sci. 2008;109:3050–61.

Tavares MR, Hrabánková K, Konefal R, Kaňa M, Říhová B, Etrych T. et al. HPMA-based copolymers carrying STAT3 inhibitor Cucurbitacin-D as stimulus-sensitive nanomedicines for oncotherapy. Pharmaceutics. 2021;13:179. PubMed PMC

Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63. PubMed

Chytil P, Kostka L, Etrych T. HPMA copolymer-based nanomedicines in controlled drug delivery. J Pers Med. 2021;11:115. PubMed PMC

Etrych T, Šubr V, Strohalm J, Šírová M, Říhová B, Ulbrich K. Fate of HPMA based polymer-doxorubicin conjugates in organism: effect of the molecular weight of polymer carrier. J Control Release. 2012;164:346–54. PubMed

Hackbarth S, Ermilov EA, Röder B. Interaction of pheophorbide a molecules covalently linked to DAB dendrimers. Opt Commun. 2005;248:295–306.

Li J, Chen C, Xia T. Understanding nanomaterial-liver interactions to facilitate the development of safer nanoapplications. Adv Mater. 2022;34:2106456. PubMed PMC

Drozdov AS, Nikitin PI, Rozenberg JM. Systematic review of cancer targeting by nanoparticles revealed a global association between accumulation in tumors and spleen. Int J Mol Sci. 2021;22:13011. PubMed PMC

Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136–51. PubMed

Maeda H, Matsumura Y. Tumorotropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst. 1989;6:193–210. PubMed

Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020;82:103–26. PubMed

Hackbarth S, Islam W, Fang J, Šubr V, Röder B, Etrych T. et al. Singlet oxygen phosphorescence detection in vivo identifies PDT induced anoxia in solid tumors. Photochem Photobiol Sci. 2019;18:1304–14. PubMed

Hackbarth S, Islam R, Šubr V, Etrych T, Fang J. Singlet oxygen in vivo - it is all about intensity. J Pers Med. 2022;12:891. PubMed PMC

Singlet Oxygen In Vivo: It Is All about Intensity-Part 2